These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 12383528)

  • 1. Measurement of nuchal translucency as a single strategy in trisomy 21 screening: should we use any other marker?
    Comas C; Torrents M; Muñoz A; Antolín E; Figueras F; Echevarría M
    Obstet Gynecol; 2002 Oct; 100(4):648-54. PubMed ID: 12383528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population.
    Pajkrt E; van Lith JM; Mol BW; Bleker OP; Bilardo CM
    Ultrasound Obstet Gynecol; 1998 Sep; 12(3):163-9. PubMed ID: 9793187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of first-trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome.
    Thilaganathan B; Slack A; Wathen NC
    Ultrasound Obstet Gynecol; 1997 Oct; 10(4):261-4. PubMed ID: 9383877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fetal nuchal translucency screening in 12495 pregnancies in Sardinia.
    Zoppi MA; Ibba RM; Floris M; Monni G
    Ultrasound Obstet Gynecol; 2001 Dec; 18(6):649-51. PubMed ID: 11844208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for trisomy 21 by fetal nuchal translucency and maternal age: a multicenter project in Germany, Austria and Switzerland.
    Gasiorek-Wiens A; Tercanli S; Kozlowski P; Kossakiewicz A; Minderer S; Meyberg H; Kamin G; Germer U; Bielicki M; Hackelöer BJ; Sarlay D; Kuhn P; Klapp J; Bahlmann F; Pruggmayer M; Schneider KT; Seefried W; Fritzer E; von Kaisenberg CS;
    Ultrasound Obstet Gynecol; 2001 Dec; 18(6):645-8. PubMed ID: 11844207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential screening for trisomy 21 by nuchal translucency measurement in the first trimester and maternal serum biochemistry in the second trimester in a low-risk population.
    Schuchter K; Hafner E; Stangl G; Ogris E; Philipp K
    Ultrasound Obstet Gynecol; 2001 Jul; 18(1):23-5. PubMed ID: 11489220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group.
    Snijders RJ; Noble P; Sebire N; Souka A; Nicolaides KH
    Lancet; 1998 Aug; 352(9125):343-6. PubMed ID: 9717920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for Down's syndrome by fetal nuchal translucency measurement in a high-risk population.
    Pajkrt E; Mol BW; van Lith JM; Bleker OP; Bilardo CM
    Ultrasound Obstet Gynecol; 1998 Sep; 12(3):156-62. PubMed ID: 9793186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities.
    Nicolaides KH
    Am J Obstet Gynecol; 2004 Jul; 191(1):45-67. PubMed ID: 15295343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study.
    Audibert F; Dommergues M; Benattar C; Taieb J; Thalabard JC; Frydman R
    Ultrasound Obstet Gynecol; 2001 Jul; 18(1):26-31. PubMed ID: 11489221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for trisomy 21 in twin pregnancies by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation.
    Sebire NJ; Snijders RJ; Hughes K; Sepulveda W; Nicolaides KH
    Br J Obstet Gynaecol; 1996 Oct; 103(10):999-1003. PubMed ID: 8863698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fetal nuchal translucency: ultrasound screening for fetal trisomy in the first trimester of pregnancy.
    Nicolaides KH; Brizot ML; Snijders RJ
    Br J Obstet Gynaecol; 1994 Sep; 101(9):782-6. PubMed ID: 7947527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
    Spencer K; Nicolaides KH
    BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency.
    Krantz DA; Hallahan TW; Orlandi F; Buchanan P; Larsen JW; Macri JN
    Obstet Gynecol; 2000 Aug; 96(2):207-13. PubMed ID: 10908764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study.
    von Kaisenberg CS; Gasiorek-Wiens A; Bielicki M; Bahlmann F; Meyberg H; Kossakiewicz A; Pruggmayer M; Kamin G; Fritzer E; Harris C; Arnold N;
    J Matern Fetal Neonatal Med; 2002 Aug; 12(2):89-94. PubMed ID: 12420837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum parameters and nuchal translucency in first trimester screening for fetal chromosomal abnormalities.
    Zimmermann R; Hucha A; Savoldelli G; Binkert F; Achermann J; Grudzinskas JG
    Br J Obstet Gynaecol; 1996 Oct; 103(10):1009-14. PubMed ID: 8863700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuchal translucency and nasal bone for trisomy 21 screening: single center experience.
    Monni G; Zoppi MA; Ibba RM; Floris M; Manca F; Axiana C
    Croat Med J; 2005 Oct; 46(5):786-91. PubMed ID: 16158472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
    Karadzov-Orlić N; Egić A; Filimonović D; Marinković M; Damnjanović-Pazin B; Milovanović Z; Joksić I; Branković S; Lukić R; Mandić V; Cerović N; Mojović D; Plamenac S; Stanković M; Maglić D; Mikovć Z
    Srp Arh Celok Lek; 2012; 140(9-10):606-11. PubMed ID: 23289277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural history of trisomy 21 fetuses with increased nuchal translucency thickness.
    Pandya PP; Snijders RJ; Johnson S; Nicolaides KH
    Ultrasound Obstet Gynecol; 1995 Jun; 5(6):381-3. PubMed ID: 7552798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.